18F-fluciclovine PET/CT improves cancer control after prostatectomy
18F-fluciclovine-PET/CT imaging led to improved outcomes with postprostatectomy salvage radiotherapy versus conventional imaging.
Related Articles
Study finds disparities in management of mCSPC
“These findings suggest that guideline recommended treatment intensification remains low for patients with mCSPC in both Medicare and the Veterans Health Administration, but especially for…
Dr. Marhamati on Aquablation in an ambulatory surgery center
“We are very excited here at Potomac Urology to be the first center in the United States, and just the second center internationally, to offer…
212Pb SPECT/CT imaging shows initial benefit, feasibility in mCRPC
“In the future, this imaging technique can help to streamline the drug development process, driving conviction in the agents we bring to larger scale trials,”…
Prostate cancer salvage therapy guideline incorporates PSMA-PET imaging
“A key piece of the guideline is that we need to offer radiation at a PSA of 0.5 ng/mL or lower and maybe even, for…
Cystoscope Preferences and Practices in Urology
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Dr. Foxton on results of drug combination with PSMA agent for prostate cancer
“In terms of the minimal overlapping toxicity, our non-clinical data from the xenograft model showed minimal toxicity with the combination,” says Caroline Foxton, PhD.
Dr. Salari on family history, germline genetic risk in favorable-risk prostate cancer
“What we found is that over a third of patients, 36%, had positive family history of either prostate, breast, or pancreatic cancer. And if you…
Addition of chemotherapy to ADT improves bPFS in prostate cancer
“Our clinical trial is the first to show a longer time to biochemical recurrence with chemotherapy plus standard hormone therapy for patients with locally advanced,…
Extended coverage expands access to iTind for BPH-related LUTS
iTind is a temporary nitinol device used to treat lower urinary tract symptoms caused by benign prostatic hyperplasia.
Clinical trial program of nadofaragene firadenovec in NMIBC expands
The 3 new additional studies are the ABLE-22, ABLE-32, and ABLE-42 clinical trials.